Q4 2022

Source filing unavailable

Q4 2022 · —

Revenue

$7.01M

−7.4% vs Q4 2021

Net Income

-$68.10M

N/M vs Q4 2021

EPS Diluted

-$0.72

N/M vs Q4 2021

Operating Income-$75,157,000N/M

Operating Cash Flow-$62,391,000N/M

Free Cash Flowderived

Same quarter

Metric	Q4 2022	Q4 2021	Q4 2020	Q4 2019
Revenue	$7.01M	$7.58M	$8.75M	$12.09M
Net Income	-$68.10M	-$57.65M	-$34.20M	-$14.60M
EPS Diluted	-$0.72	-$0.78	-$0.52	-$6.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR